| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is u...
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniatur...
https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/pdf/Vivani+Corporate+Present...
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only compan...
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is...